Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has received a consensus recommendation of "Hold" from the fourteen research firms that are currently covering the company, Marketbeat reports. Eleven equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $107.44.
Several research analysts have recently issued reports on LNTH shares. Brookline Capital Markets cut Lantheus from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. TD Cowen lowered Lantheus from a "buy" rating to a "hold" rating and cut their target price for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Truist Financial cut Lantheus from a "buy" rating to a "hold" rating and decreased their target price for the stock from $125.00 to $102.50 in a research note on Monday, August 3rd. Mizuho downgraded Lantheus from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $115.00 to $109.00 in a report on Tuesday, October 13th. Finally, Leerink Partners set a $102.50 price target on Lantheus in a report on Monday, August 3rd.
Read Our Latest Research Report on Lantheus
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. ABS Investment Management LLC acquired a new stake in Lantheus during the 2nd quarter worth $232,974,000. Western Wealth Management LLC purchased a new stake in Lantheus in the first quarter valued at $25,000. USA Financial Formulas acquired a new position in Lantheus in the third quarter valued at $41,000. Allworth Financial LP purchased a new position in shares of Lantheus during the second quarter worth about $49,000. Finally, Bessemer Group Inc. grew its holdings in shares of Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 354 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.
Lantheus Trading Up 0.1%
NASDAQ LNTH opened at $102.10 on Friday. Lantheus has a 52 week low of $52.80 and a 52 week high of $111.86. The firm has a 50 day moving average of $100.43 and a two-hundred day moving average of $93.61. The company has a quick ratio of 3.06, a current ratio of 3.25 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $6.68 billion, a PE ratio of 25.15 and a beta of 0.01.
Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.45. The business had revenue of $389.91 million during the quarter, compared to analysts' expectations of $355.74 million. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The company's revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.27 EPS. As a group, research analysts expect that Lantheus will post 4.58 EPS for the current fiscal year.
About Lantheus
(
Get Free Report)
Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company's products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.